Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

Abstract Background Colorectal cancer (CRC) is the second most common cause of cancer-related mortality worldwide with one in every five patients diagnosed with metastatic CRC (mCRC). In mCRC cases, the 5-year survival rate remains at approximately 14%, reflecting the lack of effectiveness of curren...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Susan A. Kennedy, Maria E. Morrissey, Margaret R. Dunne, Fiona O’Connell, Clare T. Butler, Mary-Clare Cathcart, Amy M. Buckley, Brian J. Mehigan, John O. Larkin, Paul McCormick, Breandán N. Kennedy, Jacintha O’Sullivan
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2020-10-01
Sarja:	BMC Cancer
Aiheet:	Angiogenesis Colorectal cancer Cysteinyl leukotriene Angiopoietin-TIE-2 signaling Combination therapy
Linkit:	http://link.springer.com/article/10.1186/s12885-020-07430-y
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!